Experts Raise New Questions About The Safety Of Anti-Alzheimer’s Drug Leqembi
https://www.forbes.com/sites/howard...t-the-safety-of-anti-alzheimers-drug-leqembi/
Medical experts are raising new questions about the safety of the anti-Alzheimer’s drug lecanemab, which is marketed as Leqembi by drugmakers Biogen and Eisai.
One study, which looked in detail at the death of a participant in a Leqembi research trial, suggests people with a condition that affects as many as half of those with Alzheimer’s disease may be at risk for severe, and even fatal, brain bleeding if they take the drug. And most troubling, the condition that endangers these people is extremely hard to diagnose. The result: Many of those who decide to take the drug won’t know how much risk they are taking.
https://www.forbes.com/sites/howard...t-the-safety-of-anti-alzheimers-drug-leqembi/
Medical experts are raising new questions about the safety of the anti-Alzheimer’s drug lecanemab, which is marketed as Leqembi by drugmakers Biogen and Eisai.
One study, which looked in detail at the death of a participant in a Leqembi research trial, suggests people with a condition that affects as many as half of those with Alzheimer’s disease may be at risk for severe, and even fatal, brain bleeding if they take the drug. And most troubling, the condition that endangers these people is extremely hard to diagnose. The result: Many of those who decide to take the drug won’t know how much risk they are taking.